Goldman Sachs Maintains Buy on Krystal Biotech, Raises Price Target to $155
Portfolio Pulse from Benzinga Newsdesk
Goldman Sachs analyst Madhu Kumar maintains a Buy rating on Krystal Biotech (NASDAQ:KRYS) and raises the price target from $135 to $155.
May 22, 2023 | 12:36 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Goldman Sachs maintains a Buy rating on Krystal Biotech and raises the price target from $135 to $155.
Goldman Sachs' maintained Buy rating and increased price target for Krystal Biotech indicates a positive outlook for the stock. This news is likely to boost investor confidence and potentially drive the stock price higher in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100